胸腺法新在慢性阻塞性肺疾病合并肺部感染中的效果及对免疫功能的影响

Effect of Thymalfasin in the Treatment of Chronic Obstructive Pulmonary Disease Complicated with Pulmonary Infection and Its Impact on Immune Function

目的探讨胸腺法新联合头孢哌酮舒巴坦钠治疗慢性阻塞性肺疾病(COPD)合并肺部感染临床效果及对免疫功能的影响。方法回顾性分析2022年3月—2023年3月收治的COPD合并肺部感染84例,根据治疗方案分为常规组39例和联合组45例。常规组予以头孢哌酮舒巴坦钠治疗,联合组在常规组基础上予以胸腺法新治疗。比较2组临床疗效、炎症反应指标、肺功能指标、血气分析指标及免疫功能。观察2组治疗期间不良反应发生情况。结果联合组临床总有效率为93.33%(42/45)高于常规组的76.92%(30/39)(P<0.05)。治疗后,联合组血清降钙素原、白细胞计数、C反应蛋白、CD8+水平、动脉血二氧化碳分压均低于常规组,第1秒用力呼气容积(FEV1)、FEV1占用力肺活量比率、动脉血氧分压及血清CD3+、CD4+水平均高于常规组(P<0.05)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论胸腺法新联合头孢哌酮舒巴坦钠可有效降低COPD合并肺部感染患者的炎症反应水平,改善肺功能,提高免疫功能和临床效果,且安全性较高。

Objective To investigate the clinical efficacy of Thymalfasin combined with Cefoperazone and Sulbactam Sodium in the treatment of chronic obstructive pulmonary disease(COPD)complicated with pulmonary infection and its impact on immune function.Methods A retrospective analysis was performed on 84 patients with COPD complicated with pulmonary infection treated from March 2022 to March 2023,who were divided into the conventional group(n=39)and the combination group(n=45)according to the treatment plan.The conventional group was treated with Cefoperazone and Sulbactam Sodium,and the combination group was treated with Thymalfasin on the basis of conventional treatment.The clinical efficacy,inflammatory response indicators,lung function indicators,blood gas analysis indicators and immune function of the two groups were compared.The occurrence of adverse reactions during treatment in the two groups was observed.Results The total effective rate of the combination group[93.33%(42/45)]was higher than that in the conventional group[76.92%(30/39)](P<0.05).After treatment,serum procalcitonin,white blood cell count,C reactive protein,CD8+level and arterial partial pressure of carbon dioxide in the combination group were lower than those in the conventional group,and forced expiratory volume in the first second(FEV1),ratio of FEV1 to forced vital capacity,partial pressure of arterial blood oxygen,and serum CD3+and CD4+levels were higher than those in conventional group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Thymalfasin combined with Cefoperazone and Sulbactam Sodium can effectively reduce the level of inflammatory response in COPD patients with pulmonary infection,improve lung function,and enhance immune function and clinical effect,with good safety.